NICE NG130 2019: ulcerative colitis management guidelines

Who it applies to

Adults, children and young people with ulcerative colitis in primary and secondary care settings.

Key recommendations

• For a first presentation or inflammatory exacerbation of proctitis, a topical aminosalicylate alone is recommended as first-line treatment to induce remission.
• For left-sided or extensive ulcerative colitis, a topical aminosalicylate combined with an oral aminosalicylate, or a high-dose oral aminosalicylate alone, can be used first line to induce remission in mild to moderate disease.
• Oral corticosteroids are added or substituted when aminosalicylates do not control symptoms adequately or are not tolerated.
• For acute severe ulcerative colitis, intravenous corticosteroids are used first line, with intravenous ciclosporin or surgery considered if there is no improvement or deterioration.
• Once remission is achieved, maintenance treatment should use the lowest effective dose of aminosalicylate, with thiopurines considered for patients who have had a severe exacerbation or more than one exacerbation in a year.
• Biologic therapies such as anti-TNF agents are options for people whose disease has not responded to, or who cannot tolerate, conventional therapy, in line with relevant technology appraisals.
• Patients should be assessed for the need for surgical referral when medical therapy fails or in acute severe disease not responding to treatment.
• Monitoring for treatment-related adverse effects, including bone marrow suppression with thiopurines and screening for skin cancer risk, is recommended during long-term therapy.
• Shared decision-making and providing information about the chronic relapsing nature of the disease, including impact on fertility, pregnancy and colorectal cancer risk, is emphasised throughout care.

Practice points for students

• Disease extent (proctitis, left-sided, extensive) determines first-line topical versus oral or combined aminosalicylate therapy.
• Acute severe colitis is a medical emergency requiring inpatient care, IV steroids, and early surgical liaison if no response within 72 hours.
• Thiopurine use requires baseline and ongoing monitoring for myelosuppression and hepatotoxicity.
• Aminosalicylates remain first line for both induction and maintenance in mild to moderate disease.
• Long-term disease activity and corticosteroid exposure inform colorectal cancer surveillance and bone health considerations.

Condition

Other guidelines on this topic

• ACG Clinical Guideline Update: Ulcerative Colitis in AdultsACG2025Official guideline
• AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative ColitisAGA2024Summary

Independent educational summary written by the WhiteCoat Pro editorial team with AI assistance and checked by a second AI model. It does not reproduce the guideline text, tables or figures, and it is not affiliated with or endorsed by NICE. It is not medical advice: always read the original guideline before applying it to patients.